Gliclazide modified release: Its place in the therapeutic armamentarium

The constraints of intensive multifactorial management of type 2 diabetes d ictate a need for effective, well-tolerated agents with simple administrati on regimens. Sulfonylureas remain the most frequently used agents, and repr esent a rational approach when consideration is given to the pathophysiolog y of this common condition. Trials of gliclazide modified release in varied populations have yielded very acceptable clinical results that support its first-line use in type 2 diabetes, including obese, elderly, and mild-to-m oderate renal insufficient patients. The simplicity of its dose regimen and its efficacy and tolerance profile may significantly contribute to improvi ng compliance. Copyright (C) 2000 by W.B. Saunders Company.